Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study

Journal of Psychiatric Research

Volumn 73, Issue , 2016, Pages 86-95

  Breitenstein, Barbara ^a,b,c   Scheuer, Sandra ^b   Brückl, Tanja Maria ^b   Meyer, Jobst ^c   Ising, Marcus ^b   Uhr, Manfred ^b   Holsboer, Florian ^a,b  

^a HMNC GmbH   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF TRIER   (Germany)

Author keywords

ABCB1; Antidepressant treatment; Major depressive disorder; MDR1; P glycoprotein; Side effects

Indexed keywords

AMITRIPTYLINE; AMITRIPTYLINOXIDE; CITALOPRAM; ESCITALOPRAM; MULTIDRUG RESISTANCE PROTEIN 1; NORTRIPTYLINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE; ABCB1 PROTEIN, HUMAN; ANTIDEPRESSANT AGENT; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ALLELE; ARTICLE; BIPOLAR DEPRESSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GROUPS BY AGE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; BLOOD; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FOLLOW UP; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PHARMACOGENETICS; PSYCHOLOGICAL RATING SCALE; TANDEM MASS SPECTROMETRY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ALLELES; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; TANDEM MASS SPECTROMETRY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84958985482     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.11.010     Document Type: Article

References (39)

1. Baumann P., Ulrich S., Eckermann G., Gerlach M., Kuss H.-J., Laux G., et al. The AGNP-TDM expert group consensus guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin. Neurosci. 2005 Jan, 7(3):231-247. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3181735&tool=pmcentrez&rendertype=abstract.
2. Breitenstein B., Scheuer S., Pfister H., Uhr M., Lucae S., Holsboer F., et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectr. 2014 Jul, 19(2):165-175. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/23880209.
3. Breitenstein B., Brückl T.M., Ising M., Müller-Myhsok B., Holsboer F., Czamara D. ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2015, 168B(4):274-283.
4. Bundgaard C., Jensen C.J.N., Garmer M. Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice. Drug Metab. Dispos. 2012 Mar, 40(3):461-466. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/22112383.
5. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Hillsdale NJ. second ed. L. Earlbaum (Ed.).
6. De Klerk O.L., Nolte I.M., Bet P.M., Bosker F.J., Snieder H., den Boer J.A., et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013 Aug, 13(4):349-353. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/22641028.
7. Doran A., Obach R.S., Smith B.J., Hosea N.A., Becker S., Callegari E., et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 2005 Jan, 33(1):165-174. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/15502009.
8. Ejsing T.B., Hasselstrøm J., Linnet K. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol. Drug Interact. 2006 Jan, 21(3-4):139-162. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/16841511.
9. Fähndrich E. Das AMDP-System: Manual zur Dokumentation Psychiatrischer Befunde 1979, Springer, Berlin. third ed.
10. Fukui N., Suzuki Y., Sawamura K., Sugai T., Watanabe J., Inoue Y., et al. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther. Drug Monit. 2007 Apr, 29(2):185-189. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/17417072.
11. Gassó P., Rodríguez N., Mas S., Pagerols M., Blázquez A., Plana M.T., et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 2014 Oct, 14(5):457-462. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/24663076.
12. GENDEP Investigators, MARS Investigators, STAR*D Investigators Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am. J. Psychiatry 2014, 170:207-217.
13. Gex-Fabry M., Eap C.B., Oneda B., Gervasoni N., Aubry J.-M., Bondolfi G., et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther. Drug Monit. 2008 Aug, 30:474-482.
14. Grauer M.T., Uhr M. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J. Psychopharmacol. 2004 Mar, 18(1):66-74. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/15107187.
15. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960 Feb, 23:56-62. Available from:. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=495331&tool=pmcentrez&rendertype=abstract.
16. Hennings J.M., Owashi T., Binder E.B., Horstmann S., Menke A., Kloiber S., et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. J. Psychiatr. Res. 2009 Jan, 43(3):215-229. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/18586274.
17. Huang X., Yu T., Li X., Cao Y., Li X., Liu B. ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients, Pharmacogenomics 2013 Nov, 14(14):1723-1730. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/24192121.
18. Jensen B.P., Roberts R.L., Vyas R., Bonke G., Jardine D.L., Begg E.J. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers. Br. J. Clin. Pharmacol. 2012 Apr, 73(4):619-628. Available from:. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3376438&tool=pmcentrez&rendertype=abstract.
19. Karlsson L., Schmitt U., Josefsson M., Carlsson B., Ahlner J., Bengtsson F., et al. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur. Neuropsychopharmacol. 2010 Sep, 20(9):632-640. , Available from:. http://www.ncbi.nlm.nih.gov/pubmed/20466523.
20. Karlsson L., Hiemke C., Carlsson B., Josefsson M., Ahlner J., Bengtsson F., et al. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacol. Berl. 2011 May, 215(2):367-377. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/21191569.
21. Karlsson L., Carlsson B., Hiemke C., Ahlner J., Bengtsson F., Schmitt U., et al. Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment. Eur. Neuropsychopharmacol. 2013 Nov, 23(11):1636-1644. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/23428338.
22. Laika B., Leucht S., Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin. Chem. 2006 May, 52(5):893-895. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/16638956.
23. Lin K.-M., Chiu Y.-F., Tsai I.-J., Chen C.-H., Shen W.W., Liu S.C., et al. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 2011 Apr, 21(4):163-170. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/20859246.
24. Nikisch G., Eap C.B., Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 2008, 58(5-6):344-347. Available from:. http://dx.doi.org/10.1016/j.phrs.2008.09.010.
25. O'Brien F.E., Dinan T.G., Griffin B.T., Cryan J.F. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br. J. Pharmacol. 2012 Jan, 165(2):289-312. Available from:. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3268186&tool=pmcentrez&rendertype=abstract.
26. O'Brien F.E., Clarke G., Dinan T.G., Cryan J.F., Griffin B.T. Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. Int. J. Neuropsychopharmacol. 2013 Dec, 16(10):2259-2272. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/23931269.
27. Perroud N., Bondolfi G., Uher R., Gex-Fabry M., Aubry J.-M., Bertschy G., et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 2011 Mar, 12(3):365-377. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/21449676.
28. Ray A., Tennakoon L., Keller J., Sarginson J.E., Ryan H.S., Murphy G.M., et al. ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. Pharmacogenomics J. 2015 Aug, Available from:. http://www.ncbi.nlm.nih.gov/pubmed/25487678.
29. Roberts R.L., Joyce P.R., Mulder R.T., Begg E.J., Kennedy M.A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002 Jan, 2(3):191-196. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/12082591.
30. Sarginson J.E., Lazzeroni L.C., Ryan H.S., Ershoff B.D., Schatzberg A.F., Murphy G.M. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010 Aug, 20(8):467-475. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/20555295.
31. Schatzberg A.F., DeBattista C., Lazzeroni L.C., Etkin A., Murphy G.M., Williams L.M. ABCB1 genetic effects on antidepressant outcomes: a Report from the iSPOT-D trial. Am. J. Psychiatry 2015 Mar 27, appiajp201514050680. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/25815420.
32. Singh A.B., Bousman C.A., Ng C.H., Byron K., Berk M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl. Psychiatry 2012, e198. Available from:. http://www.nature.com/tp/journal/v2/n11/pdf/tp2012115a.pdf.
33. Steiger A., Kimura M. Wake and sleep EEG provide biomarkers in depression. J. Psychiatr. Res. 2010 Mar, 44(4):242-252. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/19762038.
34. Uhr M., Grauer M.T. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res. 2003, 37(3):179-185. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/12650738.
35. Uhr M., Steckler T., Yassouridis A., Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacol. 2000 Apr, 22(4):380-387. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/10700657.
36. Uhr M., Grauer M.T., Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry 2003 Oct, 54(8):840-846. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/14550684.
37. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008 Jan 24, 57(2):203-209. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/18215618.
38. Uhr M., Grauer M.T., Yassouridis A., Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J. Psychiatr. Res. 2007, 41(1-2):179-188. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/16387324.
39. Wang J.-S., Zhu H.-J., Gibson B.B., Markowitz J.S., Donovan J.L., DeVane C.L. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol. Pharm. Bull. 2008 Feb, 31(2):231-234. Available from:. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2666302&tool=pmcentrez&rendertype=abstract.